Publications

Technology Status Evaluation Reports

Technology status evaluation reports provide a review of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Reports are based on an evaluation of medical literature and a search of the MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database to identify the reported adverse events of a given technology. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided. Technology status evaluation reports are scientific reviews based on expert consensus and are provided solely for educational and informational purposes.

The members of the ASGE Technology Committee provide ongoing conflict of interest (COI) disclosures throughout the development and publication of all documents in accordance with the ASGE Policy for Managing Declared Conflicts of Interests.

If you have any questions or suggestions, please contact Customer Support at Info@asge.org.

The following information is intended only to provide general information and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult your doctor about your specific condition.

Newly Published

  • Gastrointest Endosc 2025; Volume 101, Issue 3; P496-510 DOI: 10.1016/j.gie.2024.06.038

  • Gastrointest Endosc 2024; Volume 100, Issue 6; P980-993 DOI: 10.1016/j.gie.2024.05.004

  • Gastrointest Endosc 2024; Volume 100, Issue 5; p797-806 DOI: 10.1016/j.gie.2024.07.002

  • iGIE 2023; Volume 2, Issue 3; P386-394

  • iGIE 2023; Volume 2, Issue 2; P226-239

  • iGIE 2023; Volume 2, Issue 2; P240-253

  • iGIE 2023; Volume 2, Issue 2; P254-261
Upper Endoscopy
All assessments
RETs
PIVIs

  • Gastrointest Endosc 2025; Volume 101, Issue 3; P496-510 DOI: 10.1016/j.gie.2024.06.038

  • Gastrointest Endosc 2024; Volume 100, Issue 6; P980-993 DOI: 10.1016/j.gie.2024.05.004

  • Video GIE 2022; Volume 7, Issue 1; P1-20

  • Gastrointest Endosc 2021; Volume 94, Issue 4; P671-684

  • Gastrointest Endosc 2021; Volume 94, Issue 1; P3-13

  • Video GIE 2020; Volume 5, Issue 12; P598-613

  • Gastrointest Endosc Sept 2020, Volume 92, Issue 3, Pages 483-491 / DOI:

  • GIE 2019; Volume 90, Issue 3; P325-334

  • Gastrointest Endosc July 2019 Volume 90, Issue 1, Pages 27–34

  • Gastrointest Endosc July 2019 Volume 90, Issue 1, Pages 13–26

  • Endoscopic anti-reflux devices (with videos) 2017

    Gastrointest Endosc 2017; Volume 86, Issue 6; P931-948

  • Gastrointest Endosc 2016;83:1051–1060

  • Gastrointest Endosc 2016;83:684–698.e7

  • Gastrointest Endosc 2015;82:215–226

  • Gastrointest Endosc 2015;82:975-990

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121
Colonoscopy
All assessments
PIVIs

  • Gastrointest Endosc 2021; Volume 94, Issue 1; P1-2

  • Volume 92, Issue 3, Pages 474-482

  • Gastrointest Endosc March 2018 Volume 87, Issue 3, Pages 625–634

  • Gastrointest Endosc 2015;81:1122–1129

  • Gastrointest Endosc 2015;81:502.e1–502.e16

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121
Bariatric Endoscopy
All assessments
RETs
PIVIs

  • Gastrointest Endosc Sept 2020, Volume 92, Issue 3, Pages 492-507 / DOI

  • Gastrointest Endosc 2015;82:425–438.e5

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121
ERCP

  • VideoGIE 2018;3:329-338

  • Gastrointest Endosc 2016;84:209–221

  • Gastrointest Endosc 2016;83:1061–1075
EUS
All assessments
RETs

  • Gastrointest Endosc 2021; Volume 94, Issue 4; P671-684

  • Gastrointest Endosc 2021; Volume 93, Issue 2; P323-333

  • VideoGIE 2017;2:35–45

  • Gastrointest Endosc May 2017, Volume 85, Issue 5, Pages 883–888

  • Gastrointest Endosc 2017;85:465–481

  • Gastrointest Endosc 2015;82:189–202

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121
Endoscope Design/Reprocessing
All assessments 
RETs

  • iGIE 2023; Volume 2, Issue 3; P386-394

  • iGIE 2023; Volume 2, Issue 2; P240-253

  • Gastrointest Endosc 2021; Volume 94, Issue 3; P457-470

  • Gastrointest Endosc 2021; Volume 93, Issue 5; P997-1005

  • GIE 2019; Volume 90, Issue 1; P1-12

  • Gastrointest Endosc 2016;84:885–892

  • Gastrointest Endosc 2016;83:857–865

  • iGIE 2023; Volume 2, Issue 3; P386-394

  • iGIE 2023; Volume 2, Issue 2; P240-253

  • Gastrointest Endosc 2021; Volume 93, Issue 5; P997-1005
Other Imaging Techniques
All assessments
RETs

  • Gastrointest Endosc 2021; Volume 93, Issue 4; P784-796

  • Gastrointest Endosc 2015;81:249–261
Therapeutic GI Devices
All assessments
RETs

Radiofrequency ablation devices 2017

Oct 2, 2017, 08:24
Background Radiofrequency ablation (RFA) uses thermal energy to accomplish targeted tissue destruction. Within the GI tract, RFA was initially studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be a common application. Indications for RFA within the GI tract continue to evolve. It has been used in the treatment of esophageal squamous cell dysplasia, gastric antral vascular ectasia (GAVE), radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia, among other conditions.1, 2, 3, 4, 5, 6, 7, 8, 9 This report focuses on devices and techniques used to perform RFA in the GI tract. Technology under review RFA devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the RFA device in the radiofrequency range of 450 to 500 kHz. This current generates thermal energy within tissue in direct contact with the radiofrequency (RF) electrode, resulting in coagulation necrosis of the targeted tissue. The spacing and geometry of the electrodes on the RFA device and the preset parameters (energy, power) within the RFA generator allow achievement of a consistent depth of ablation. For instance, in the treatment of mucosal pathologic conditions, the dosimetry is designed to yield an ablation depth to the muscularis mucosae (700-800 μm deep).10, 11
Title : Radiofrequency ablation devices 2017
URL :
Doi org link : http://dx.doi.org/10.1016/j.vgie.2017.06.002
Volume : VideoGIE October 2017 Volume 2, Issue 10, Pages 252–259
Select a choice : Keep
Content created : Sep 28, 2017, 23:00
ExternalPK :
File size :
Categories :
  • Ablation
  • Lower GI
  • Upper GI
Tags :
PIIS2468448117301121

  • iGIE 2023; Volume 2, Issue 2; P226-239
Miscellaneous
All assessments
RETs

Submucosal injection fluid and tattoo agents 2024

Nov 5, 2024, 11:24
Title : Submucosal injection fluid and tattoo agents 2024
URL :
Doi org link : https://www.giejournal.org/article/S0016-5107(24)03347-9/fulltext
Volume : Gastrointest Endosc 2024; Volume 100, Issue 5; p797-806 DOI: 10.1016/j.gie.2024.07.002
Select a choice : Keep
Content created :
ExternalPK :
File size :
Categories :
Tags :
  • misc

  • Gastrointest Endosc 2024; Volume 100, Issue 5; p797-806 DOI: 10.1016/j.gie.2024.07.002

  • iGIE 2023; Volume 2, Issue 2; P254-261

In Progress Technology Assessments

Endoscopic closure devices

2025

iStock-1189305225(1)

Practice Guidelines

View all